Semaglutide + Cagrilintide (5mg + 5mg)

CagriSema is a precision dual-agonist research blend combining Semaglutide (GLP-1 receptor agonist) and Cagrilintide (long-acting amylin analog) — two complementary metabolic hormones that target appetite, satiety, and energy balance through distinct but synergistic receptor pathways.

Semaglutide suppresses appetite via central hypothalamic GLP-1 receptor signalling, slows gastric emptying, and improves insulin sensitivity. Its ~7-day half-life enables stable once-weekly dosing. Cagrilintide is a long-acting amylin analog that signals fullness through the area postrema and nucleus accumbens, further delays gastric emptying, and suppresses post-prandial glucagon secretion — mechanisms entirely complementary to GLP-1. Together they produce additive appetite suppression through two independent neural and peripheral circuits.

Phase 2 clinical trials of co-administered CagriSema demonstrated mean weight reduction of ~15–17% at 32 weeks — significantly superior to semaglutide monotherapy — with continued progression beyond. In type 2 diabetes cohorts, the combination achieved substantial HbA1c reductions alongside robust body weight reduction. The dual-pathway mechanism consistently outperforms either agent in isolation.